Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

368/433 Matches for
“diagnosis”

“diagnosis” Clear all
  1. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.

    Calès P et al. · Liver Int · 2008 Match 100

    ### Background The reliable diagnosis rate of diagnostic tests is provided by their…

    FibroTest HCV

  2. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 100

    …The reference was fibrosis Metavir staging. ### Results Diagnosis of significant fibrosis (Metavir…

    FibroTest Alcohol HBV HCV +2

  3. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.

    Calès P et al. · Gastroenterol Clin Biol · 2008 Match 100

    ### Objective To evaluate the rates of reliable diagnosis of cirrhosis by two…

    FibroTest HCV

  4. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.

    Boursier J et al. · Eur J Gastroenterol Hepatol · 2009 Match 100

    …This specific test provided a 100% positive predictive value for cirrhosis diagnosis

    FibroTest HCV

  5. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 100

    …Currently, its diagnosis requires liver biopsy, an invasive procedure not free from…

    SteatoTest

  6. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Match 100

    …but provide only a binary diagnosis of significant fibrosis (SAFE or BA…

    FibroTest HCV

  7. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.

    Boursier J et al. · Am J Gastroenterol · 2011 Match 100

    …used for the non-invasive diagnosis of liver fibrosis. Detailed fibrosis stage…

    FibroTest HCV

  8. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 100

    …For the diagnosis of cirrhosis, EFT-F4 performances were greater than those…

    Elasto-FibroTest FibroTest HCV

  9. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 99

    …All biopsy specimens were reanalysed independently to confirm the diagnosis of NRH…

    FibroTest Other

  10. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.

    Chen J et al. · J Clin Lab Anal · 2013 Match 99

    ### Background Noninvasive laboratory tests have been widely used in the diagnosis of…

    FibroTest HBV

  11. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 99

    …For the diagnosis of advanced fibrosis (F≥3), the AUROC curves were…

    FibroTest Alcohol

  12. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

    Calès P et al. · J Hepatol · 2010 Match 99

    …Reliable individual diagnosis based on predictive values > or = 90% distinguished three test…

    FibroTest HCV HIV

  13. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 99

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  14. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 99

    …AUROCs of NT for the diagnosis of NASH in the training and…

    NashTest Metabolic

  15. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 99

    …noninvasive methods for their respective diagnosis: magnetic resonance imaging proton-density-fat…

    FibroTest NashTest SteatoTest HIV

  16. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 98

    …performance of CAP for the diagnosis of steatosis in patients with chronic…

    SteatoTest Metabolic

  17. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 98

    …For the diagnosis of all fibrosis stages as presumed by FT, the…

    FibroTest Alcohol HBV HCV +3

  18. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 98

    …The diagnosis may be difficult, because laboratory and imaging tests are not…

    FibroTest Metabolic

  19. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022 Match 98

    …criteria) at the time of diagnosis. There is no non-invasive method…

    FibroTest Alcohol HBV HCV +1

  20. Guidelines for the diagnosis of uncomplicated cirrhosis.

    Fontaine H et al. · Gastroenterol Clin Biol · 2007 Match 98

    FibroTest Alcohol HBV HCV +2

  21. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 98

    …of serum markers for the diagnosis of significant fibrosis. The combination of…

    FibroTest HBV HCV HIV

  22. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010 Match 98

    …Compared to binary diagnosis, fibrosis stage classification increased discrimination, with an increased…

    FibroTest HCV

  23. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 98

    …Aims To assess Fibroscan for non-invasive diagnosis of asymptomatic liver fibrosis…

    FibroTest Alcohol

  24. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 97

    …Study of Obesity for the diagnosis, treatment and follow-up of non…

    FibroTest NashTest Metabolic

  25. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 97

    ### Background Liver fibrosis is a sign of advanced liver disease and is…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  26. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.

    Bourliere M et al. · Aliment Pharmacol Ther · 2008 Match 97

    …or =F2, F3F4 and F4 diagnosis were 0.82, 0.84 and…

    FibroTest HCV

  27. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 97

    …These AFEF guidelines on the non-invasive diagnosis and follow up of…

    FibroTest HCV

  28. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

    Castéra L et al. · J Hepatol · 2009 Match 97

    ### Background/Aims To assess prospectively the accuracy of transient elastography (TE, FibroScan…

    FibroTest HCV

  29. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 97

    …the M probe in the diagnosis of cirrhosis (area under under the…

    FibroTest Alcohol HBV HCV +2

  30. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 97

    …the best algorithms for the diagnosis of significant fibrosis in chronic hepatitis…

    FibroTest HCV

  31. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 96

    …FibroTest and LSM for the diagnosis of fibrosis using sAUROC, the pairwise…

    FibroTest HCV

  32. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.

    Thabut D et al. · Liver Int · 2006 Match 96

    …of liver fibrosis, for the diagnosis of LOV in cirrhotic patients. ### Methods…

    FibroTest Alcohol HBV HCV

  33. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 96

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  34. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 96

    …The performance of biopsy was lower for the diagnosis of F2 vs…

    FibroTest Alcohol HBV HCV +3

  35. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 96

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  36. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 96

    …FibroTest and Fibroscan for the diagnosis of advanced fibrosis and cirrhosis in…

    FibroTest HCV

  37. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 96

    …as part of an initial diagnosis or of a follow-up assessment…

    ActiTest FibroTest Alcohol HBV +3

  38. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 95

    …The accuracy for the diagnosis of histologic steatosis was best with MR…

    FibroTest SteatoTest Other

  39. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 95

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  40. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 95

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  41. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 95

    …For the diagnosis of significant fibrosis by the METAVIR scoring system, the…

    ActiTest FibroTest HCV

  42. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Match 95

    ### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…

    FibroTest HCV

  43. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Match 95

    …A clinically relevant gain in the likelihood of diagnosis was achieved in…

    FibroTest HBV HCV HIV

  44. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 95

    diagnosis) and a girl (aged 10.6 and 13 years at diagnosis

    FibroTest Metabolic

  45. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

    de Lédinghen V et al. · J Pediatr Gastroenterol Nutr · 2007 Match 95

    …For the diagnosis of cirrhosis, the area under the receiver operating characteristic…

    FibroTest HBV HCV Other

  46. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 94

    …with NAFLD, including diagnosis and quantification of steatosis, diagnosis of NASH and…

    ActiTest FibroTest NashTest SteatoTest +1

  47. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 94

    FibroTest HCV

  48. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.

    Bosselut N et al. · Clin Chim Acta · 2013 Match 94

    …of liver biopsies for the diagnosis of significant fibrosis. ### Conclusion Coopscore© provides…

    FibroTest HCV

  49. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    Leroy V et al. · J Hepatol · 2014 Match 94

    …hepatitis C, especially for the diagnosis of extensive fibrosis and cirrhosis, with…

    FibroTest HBV HCV

  50. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 94

    …standard for establishing a definite diagnosis and assessing the fibrosis stage of…

    FibroTest Alcohol

  51. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.

    Carlson JJ et al. · J Gastroenterol Hepatol · 2009 Match 94

    …invasive testing strategies in the diagnosis of significant liver fibrosis (Metavir score…

    FibroTest

  52. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 94

    …The assessment of disease progression not only provides useful information for diagnosis

    FibroTest HCV

  53. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 93

    ActiTest AshTest FibroTest NashTest +6

  54. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 93

    …ALD is acceptable for the diagnosis of significant fibrosis or cirrhosis but…

    FibroTest Alcohol

  55. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 93

    FibroTest Alcohol HBV HCV +3

  56. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 93

    …The κ between diagnosis of fatty liver by SteatoTest (≥ S2) and by…

    SteatoTest Metabolic

  57. Combination of fibrosis tests: sequential or synchronous?

    Boursier J et al. · Hepatology · 2009 Match 93

    FibroTest HCV

  58. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 93

    …The analysis of 924 estimates for the diagnosis of bridging fibrosis, cirrhosis…

    ActiTest FibroTest HBV

  59. Noninvasive assessment of portal hypertension in patients with cirrhosis.

    Thabut D et al. · Hepatology · 2011 Match 93

    Severe portal hypertension is responsible for complications and death. Although measurement of…

    FibroTest Alcohol HBV HCV +3

  60. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 92

    …The FibroTest in point 0.51 for the diagnosis of fibrosis obtained…

    FibroTest Other

  61. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011 Match 92

    FibroTest HBV HCV HIV

  62. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 92

    …of biomarkers (AshTest) for the diagnosis of alcoholic steato-hepatitis (ASH), in…

    AshTest Alcohol

  63. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Match 92

    …Fibrotest®, interpretable Fibroscan™, Fibrometer®, and Hepascore® perform best and similarly for diagnosis

    FibroTest HCV

  64. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 92

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  65. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 92

    …NashTest (BioPredictive) for the categorical diagnosis of nonalcoholic steatohepatitis; and AshTest for…

    ActiTest AshTest FibroTest NashTest +7

  66. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.

    Miailhes P et al. · J Viral Hepat · 2011 Match 92

    …The diagnosis accuracy of TE was calculated using receiver operating characteristic (ROC…

    FibroTest HBV HIV

  67. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 92

    …However, recent advances in diagnosis and treatment, combined with the risk of…

    FibroTest Metabolic

  68. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 91

    …For the diagnosis of F4, the AUROC was very high, .95 for…

    FibroTest Alcohol

  69. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 91

    …The accuracy (AUROC) for the diagnosis of significant fibrosis (F≥2) for…

    FibroTest HBV HCV Other

  70. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 91

    …glycans as markers for the diagnosis of cirrhosis in patients with chronic…

    FibroTest HBV

  71. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

    Cacoub P et al. · J Hepatol · 2008 Match 91

    …and 0.89 for the diagnosis of F2, respectively. The correlation coefficient…

    FibroTest HCV HIV

  72. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 91

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  73. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 91

    …and 0.85 for the diagnosis of significant fibrosis (F > or = 2…

    FibroTest Alcohol HBV HCV +2

  74. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.

    Varaut A et al. · Transplantation · 2005 Match 91

    ### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…

    FibroTest HCV

  75. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2012 Match 90

    ### Background Preliminary data suggest that performance of non-invasive markers for liver…

    FibroTest HCV

  76. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 90

    …For the diagnosis of grade 2-4 steatosis, the sensitivity of SteatoTest…

    SteatoTest Alcohol HBV HCV +1

  77. Diagnosis of fibrosis and cirrhosis. Liver biopsy is not always necessary.

    · Prescrire Int · 2010 Match 90

    Needle biopsy of the liver is considered the "gold-standard" for diagnosis

    FibroTest HCV

  78. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.

    Köksal İ et al. · Turk J Gastroenterol · 2018 Match 90

    ### Background/Aims The hepatitis C virus (HCV) infection is important cause of…

    FibroTest HCV

  79. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 90

    …discuss future directions and new opportunities in the noninvasive diagnosis of ALD.

    FibroTest Alcohol

  80. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 90

    …uncertainty of biomarkers for the diagnosis of the early stage of clinically…

    FibroTest-T2D Metabolic

  81. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 90

    …Thus, early and accurate diagnosis of cirrhosis is important to allow an…

    FibroTest HBV

  82. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 89

    …For the diagnosis of advanced fibrosis, the standardized area under the receiver…

    FibroTest HBV

  83. Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C (Letter)

    Match 89

    FibroTest HCV

  84. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 89

    …As waiting for the perfect biomarker for the diagnosis of advanced fibrosis…

    ActiTest FibroTest SteatoTest Alcohol +5

  85. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 89

    …For FibroTest, the mean diagnostic value for the diagnosis of advanced fibrosis…

    FibroTest Alcohol HBV HCV +3

  86. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 89

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  87. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001 Match 89

    …basic serum biochemical markers for diagnosis of clinically significant fibrosis (including early…

    FibroTest HCV

  88. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 89

    ### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…

    FibroTest SteatoTest Alcohol

  89. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 89

    …new quantitative test for the diagnosis of nonalcoholic steatohepatitis (NASH) using a…

    FibroTest NashTest SteatoTest Metabolic

  90. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 88

    ### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…

    FibroTest Other

  91. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 88

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  92. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 88

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  93. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 88

    …not different AUROCs for the diagnosis of advanced fibrosis (F2F3F4): 0.86…

    FibroTest Metabolic

  94. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 88

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  95. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 88

    …in CHB (P = 0.007). Diagnosis performance of FR for significant fibrosis…

    FibroTest HBV HCV

  96. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014 Match 88

    ### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…

    FibroTest HCV

  97. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 87

    ### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…

    NashTest SteatoTest Metabolic

  98. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.

    Lewin M et al. · Hepatology · 2007 Match 87

    …ADC) of water, for the diagnosis of liver fibrosis in patients with…

    FibroTest HCV

  99. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 87

    FibroTest Alcohol HBV HCV +1

  100. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 87

    …levels upon initial acute HCV diagnosis. Treatment with interferon-based therapy was…

    FibroTest HCV HIV

  101. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.

    Halfon P et al. · Am J Gastroenterol · 2006 Match 87

    …FT area under ROC curve for diagnosis of activity (A2-A3), significant…

    ActiTest FibroTest HCV

  102. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 87

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  103. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 87

    …The biochemical markers have significant predictive values both for the diagnosis of…

    ActiTest FibroTest HCV

  104. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 87

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  105. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 86

    ### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…

    FibroTest HBV

  106. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 86

    FibroTest SteatoTest Metabolic

  107. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

    Castera L et al. · J Hepatol · 2007 Match 86

    FibroTest HCV

  108. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 86

    …methods in NASH screening and diagnosis. Routine radiologic modalities were found to…

    FibroTest Metabolic

  109. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 86

    …the panel provides non-invasive diagnosis of the stages of fibrosis, and…

    FibroTest NashTest-2 SteatoTest Metabolic

  110. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 86

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  111. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 86

    …operating curve (AUROC) for F3F4 diagnosis from the prevalences of fibrosis stages…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  112. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 85

    …The mean diagnostic value for the diagnosis of advanced fibrosis assessed using…

    ActiTest FibroTest SteatoTest Alcohol +5

  113. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

    Myers RP et al. · Am J Gastroenterol · 2002 Match 85

    …For diagnosis of advanced fibrosis (F3 and F4), the areas under the…

    FibroTest HCV

  114. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 85

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  115. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Match 85

    …The FibroTest area under the ROC curves for the diagnosis of advanced…

    FibroTest HCV

  116. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 85

    …ROC curves (AUROCs) for the diagnosis of bridging fibrosis (F2/F3/F4…

    FibroTest Alcohol HBV HCV +2

  117. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 85

    …The diagnostic accuracy (AUROC) for the diagnosis of large oesophageal varices was…

    FibroTest Alcohol HBV HCV +3

  118. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007 Match 85

    ### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…

    FibroTest HCV

  119. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 84

    …The AUROC for the diagnosis of the intermediate adjacent stages F2 vs…

    FibroTest Alcohol HBV HCV +1

  120. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 84

    ### Background Noninvasive tests are crucial for the management and follow-up of…

    ActiTest FibroTest AIH

  121. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 84

    …and plasma biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and advanced…

    FibroTest NashTest-2 Metabolic

  122. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 84

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  123. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 84

    …Non-invasive methods for the diagnosis of liver fibrosis, such as transient…

    FibroTest Other

  124. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 84

    …7-96.6%) for the diagnosis of Covid-19. The area under…

    FibroTest COVID

  125. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.

    Fierbinteanu-Braticevici C et al. · World J Gastroenterol · 2009 Match 84

    …P < 0.001) for the diagnosis of significant fibrosis (F >or= 2…

    FibroTest HCV

  126. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 84

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  127. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Match 83

    ### Background Liver biopsy is an imperfect gold standard for assessing the disease…

    FibroTest HCV

  128. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 83

    …The overall accuracy of AT for the diagnosis of any activity grade…

    ActiTest HCV

  129. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 83

    …Taken together, the developments in screening, diagnosis and treatment will likely increase…

    ActiTest FibroTest HCV

  130. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 83

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  131. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.

    Boursier J et al. · BMC Gastroenterol · 2011 Match 83

    ### Background Non-invasive tests have been constructed and evaluated mainly for binary…

    FibroTest HCV

  132. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 83

    …This study evaluated FibroMax™ for noninvasive diagnosis of steatosis in patients with…

    HCV

  133. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 83

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  134. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

    Mallet V et al. · Aliment Pharmacol Ther · 2009 Match 82

    ### Background The Fib-4 index is a simple and inexpensive biomarker to…

    FibroTest HBV

  135. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 82

    ### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…

    ActiTest FibroTest HCV

  136. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Match 82

    FibroTest HCV

  137. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 82

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  138. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 82

    …provides a reliable and reproducible diagnosis and grading/staging of the three…

    ActiTest FibroTest SteatoTest Metabolic

  139. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007 Match 82

    …The areas under the receiver operating characteristic curves for the diagnosis of…

    FibroTest Alcohol HBV HCV +2

  140. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 82

    ### Background And Aims The PGAA index was one of the first composite…

    FibroTest Alcohol

  141. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 81

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  142. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 81

    …AUROCs for diagnosis of F> or =3 in HCV patients and non…

    FibroTest Alcohol HBV HCV +2

  143. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 81

    FibroTest Alcohol

  144. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 81

    …curves (AUROCs), 99 for the diagnosis of advanced fibrosis and 86 for…

    FibroTest HBV HCV

  145. Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?

    Sebastiani G et al. · Hepatology · 2012 Match 81

    FibroTest HCV

  146. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 81

    …the best algorithms for the diagnosis of significant fibrosis in chronic hepatitis…

    FibroTest HCV

  147. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 81

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  148. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014 Match 81

    …With the exception of the most advanced stages, the diagnosis of liver…

    FibroTest HCV

  149. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 80

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  150. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 80

    …suspected ALD to confirm the diagnosis, exclude other or additional liver pathologies…

    FibroTest Alcohol

  151. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 80

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  152. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 80

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  153. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 80

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  154. Changes of non-invasive markers and FibroScan values during HCV treatment.

    Vergniol J et al. · J Viral Hepat · 2009 Match 80

    The recent advent of non-invasive methods for assessment of fibrosis allows…

    FibroTest HCV

  155. [The scope of clinical applications of noninvasive methods for the assessment of liver fibrosis results of orginial studies in a multi-field hospital].

    Pavlov ChS et al. · Klin Med (Mosk) · 2009 Match 80

    …the optimal algorithm for the diagnosis of hepatic fibrosis in patients with…

    FibroTest HBV HCV

  156. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 79

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  157. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Match 79

    ### Background/Aims The aim of this study was to compare the performance…

    FibroTest HBV HIV

  158. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 79

    …tests of fibrosis allows accurate diagnosis of cirrhosis and reduces the need…

    FibroTest Alcohol HBV HCV +1

  159. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 79

    FibroTest Metabolic

  160. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Match 79

    ### Aim To assess the usefulness of FibroTest to forecast scores by constructing…

    FibroTest HCV

  161. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

    Uyar C et al. · Indian J Pathol Microbiol · 2010 Match 79

    ### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…

    ActiTest FibroTest HBV HCV

  162. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 79

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  163. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

    Sène D et al. · Clin Biochem · 2006 Match 78

    ### Objective And Methods We assessed the reliability of non-invasive biological scoring…

    ActiTest FibroTest HCV

  164. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 78

    …proposed an algorithm for the diagnosis of advanced liver fibrosis. We aimed…

    FibroTest Metabolic

  165. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 78

    …There was no discrepancy between the initial diagnosis and the diagnosis proposed…

    Metabolic

  166. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 78

    Alcohol is one of the main factors of liver damage. The evaluation…

    FibroTest Alcohol

  167. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Match 78

    …Non-invasive panels for the diagnosis of steatosis, NASH and/or fibrosis…

    ActiTest FibroTest NashTest SteatoTest +1

  168. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 78

    …first-generation SteatoTest for the diagnosis of steatosis, without the limitations of…

    NashTest-2 SteatoTest-2 Metabolic

  169. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Match 78

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  170. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 78

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  171. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 77

    …LSM) by FibroScan for the diagnosis of liver fibrosis and the evaluation…

    FibroTest Metabolic

  172. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

    Sebastiani G et al. · J Hepatol · 2006 Match 77

    ### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…

    FibroTest HCV

  173. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 77

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  174. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 77

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  175. La Haute Autorite de Sante (HAS) in France— Diagnosis of uncomplicated cirrhosis (Accessed December 2011)

    Match 77

    FibroTest Alcohol HBV HCV +2

  176. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.

    Alric L et al. · Transpl Int · 2009 Match 77

    …7.1 kPa for LSM. Diagnosis of patients with severe liver fibrosis…

    FibroTest HBV HCV

  177. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.

    Bonnard P et al. · Am J Trop Med Hyg · 2010 Match 77

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…

    FibroTest HBV

  178. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 76

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  179. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 76

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…

    FibroTest

  180. A novel panel of blood markers to assess the degree of liver fibrosis.

    Calès P et al. · Hepatology · 2005 Match 76

    The objective was to develop new blood tests to characterize different fibrosis…

    FibroTest Alcohol HBV HCV

  181. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 76

    …alternatives to biopsy for the diagnosis of fibrosis in patients with chronic…

    FibroTest Alcohol HBV HCV +3

  182. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014 Match 76

    Liver biopsy, which was traditionally considered to be the gold standard for…

    FibroTest HBV HCV

  183. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 76

    ActiTest FibroTest HCV

  184. Implementing non-invasive markers for liver fibrosis in clinical practice.

    Sebastiani G et al. · J Hepatol · 2008 Match 76

    FibroTest HCV

  185. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 75

    FibroTest Metabolic

  186. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.

    Callewaert N et al. · Nat Med · 2004 Match 75

    We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers…

    FibroTest Alcohol Other

  187. Poynard T, Ratziu V, Imbert-Bismut F, Munteanu M

    Match 75

    ActiTest FibroTest HCV

  188. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 75

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  189. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.

    Bonnard P et al. · J Viral Hepat · 2015 Match 75

    In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…

    FibroTest HCV

  190. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 75

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  191. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 75

    ### Background Few data are available on chronic hepatitis C (CHC) in elderly…

    FibroTest HCV

  192. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.

    Poynard T et al. · J Viral Hepat · 2002 Match 75

    A liver fibrosis index was recently prospectively validated in a cross-sectional…

    FibroTest HCV

  193. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 74

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver…

    FibroTest Alcohol HBV HCV +1

  194. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 74

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  195. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.

    Cheng J et al. · PLoS One · 2015 Match 74

    ### Background And Aims Noninvasive models have been developed for fibrosis assessment in…

    FibroTest HBV

  196. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

    Morra R et al. · Aliment Pharmacol Ther · 2007 Match 74

    ### Background FibroTest has been validated for the diagnosis of liver fibrosis in…

    FibroTest Alcohol HBV HCV +1

  197. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?

    Maor Y et al. · Haemophilia · 2006 Match 74

    Liver biopsy remains the gold standard for the evaluation of fibrosis despite…

    FibroTest HCV

  198. Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J, Benhamou Y

    Match 74

    ActiTest FibroTest HCV

  199. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 74

    …provide a mechanism for earlier diagnosis. These tests have been extensively validated…

    FibroTest Other

  200. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 73

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  201. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 73

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  202. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 73

    …range of LSM, accuracy for diagnosis of significant fibrosis according to LB…

    FibroTest HBV

  203. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 73

    …The diagnosis of dependency was made according to the ICD-10 WHO…

    FibroTest Alcohol

  204. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 73

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  205. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014 Match 73

    …The diagnosis is presently limited to invasive procedures such as endoscopy. Noninvasive…

    FibroTest Other

  206. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 73

    ### Background And Aims Real-time shear wave elastography (2D-SWE) is a…

    ActiTest FibroTest SteatoTest Alcohol +3

  207. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 73

    ActiTest AshTest FibroTest NashTest +7

  208. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 72

    ### Background The diagnosis of alcoholic liver diseases is based on the history…

    ActiTest AshTest FibroTest NashTest +2

  209. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 72

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  210. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 72

    Haemophilia is an entity, wherein the HCV infection rate is greater than…

    FibroTest HCV

  211. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 72

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  212. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 72

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  213. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 72

    ### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…

    ActiTest FibroTest Alcohol HBV +1

  214. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.

    Castera L et al. · Hepatology · 2006 Match 72

    FibroTest HCV

  215. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 71

    ### Background Although the FibroTest has been validated as a biomarker to determine…

    FibroTest Alcohol HBV HCV +1

  216. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 71

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  217. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 71

    ### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…

    FibroTest HIV

  218. [FibroTest-ActiTest for predicting liver fibrosis and inflammatory activity in Chinese patients with chronic hepatitis B]. Key publication

    Gui HL et al. · Zhonghua Gan Zang Bing Za Zhi · 2008 Match 71

    …Areas under ROC curve for diagnosis of significant inflammation (A2-A4), significant…

    FibroTest HBV

  219. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Match 71

    ### Unlabelled The staging of liver fibrosis is pivotal for defining the prognosis…

    FibroTest HCV

  220. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 71

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  221. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 71

    ### Background & Aims The first aim was to extend the validation of FibroTest…

    ActiTest FibroTest HBV

  222. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 70

    FibroTest HCV

  223. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Match 70

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  224. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 70

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  225. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 70

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  226. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 70

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  227. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025 Match 70

    In this article, we comment on the article by Peta _et al…

    ActiTest FibroTest AIH

  228. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 70

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  229. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 70

    …Furthermore, NAFLD diagnosis relied exclusively on circulating biomarker-based liver scores, without…

    FibroTest NashTest SteatoTest Metabolic

  230. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 69

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  231. Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.

    Maor Y et al. · Haemophilia · 2010 Match 69

    Non-invasive modalities to estimate fibrosis stage are desirable in hepatitis C…

    FibroTest HCV

  232. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 69

    FibroTest HBV

  233. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 69

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  234. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 69

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  235. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.

    Poynard T et al. · J Viral Hepat · 2008 Match 69

    FibroTest HCV

  236. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 69

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  237. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 68

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  238. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 68

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  239. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 68

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  240. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 68

    ActiTest FibroTest Alcohol HBV +3

  241. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.

    Usluer G et al. · Eur J Clin Microbiol Infect Dis · 2012 Match 68

    The aim of this study was to compare the results of nine…

    FibroTest HCV

  242. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 68

    ActiTest FibroTest NashTest-2 Metabolic

  243. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.

    Liu S et al. · PLoS One · 2011 Match 68

    ### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…

    FibroTest HCV

  244. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 67

    ### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…

    FibroTest

  245. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 67

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  246. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Match 67

    FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…

    ActiTest FibroTest HCV

  247. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 67

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  248. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 67

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  249. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 67

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  250. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020 Match 67

    Fontan-palliated patients are at risk for the development of Fontan-associated…

    FibroTest Other

  251. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 67

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  252. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 66

    FibroTest Alcohol HBV HCV +1

  253. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 66

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  254. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 66

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  255. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 66

    ### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…

    ActiTest FibroTest HBV

  256. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 66

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  257. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

    Le Calvez S et al. · Hepatology · 2004 Match 66

    FibroTest HCV

  258. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

    Poynard T et al. · Ann Intern Med · 2013 Match 66

    FibroTest HCV

  259. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.

    Pokorska-Śpiewak M et al. · Clin Exp Hepatol · 2017 Match 65

    ### Aim Of The Study Was to evaluate liver disease severity in children…

    ActiTest FibroTest HBV HCV

  260. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 65

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  261. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 65

    ### Background And Aims Hepatobiliary disorders, associated either with extraintestinal manifestations or with…

    FibroTest Other

  262. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 65

    ### Introduction We present two consensus definitions of advanced and late stage liver…

    FibroTest HBV HCV

  263. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

    Schmid P et al. · PLoS One · 2015 Match 65

    ### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…

    FibroTest HCV HIV

  264. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 65

    FibroTest Other

  265. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Match 65

    ### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…

    ActiTest FibroTest HCV

  266. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 64

    …There is great interest in determining non-invasive markers for the diagnosis

    FibroTest HCV

  267. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 64

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  268. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 64

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  269. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 64

    ### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…

    FibroTest HCV

  270. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 64

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  271. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 64

    ### Background No blood test has been shown to be effective in the…

    FibroTest LCR1 LCR2 Alcohol +3

  272. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.

    Bourliere M et al. · J Viral Hepat · 2006 Match 64

    …For the diagnosis of significant fibrosis, respective AUCs of FT, APRI and…

    FibroTest HCV

  273. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

    Park MS et al. · PLoS One · 2013 Match 64

    ### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…

    FibroTest HBV

  274. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 63

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  275. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 63

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  276. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Match 63

    In chronic hepatitis C, biopsy is the gold standard for assessment of…

    FibroTest HCV

  277. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 63

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest

  278. Diagnostic value of FibroTest with normal serum aminotransferases.

    Poynard T et al. · Hepatology · 2006 Match 63

    FibroTest HCV

  279. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.

    Shaheen AA et al. · HIV Clin Trials · 2008 Match 63

    ### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…

    FibroTest HCV HIV

  280. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 63

    ### Background There is a clear need for better biomarkers of drug-induced…

    ActiTest FibroTest Other

  281. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

    Patel K et al. · Aliment Pharmacol Ther · 2016 Match 62

    ### Background Assessment of fibrosis progression in chronic liver disease relies upon non…

  282. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 62

    ### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…

    FibroTest Metabolic

  283. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Match 62

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  284. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 62

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  285. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Match 62

    ### Background Elevation of liver enzymes in rheumatoid arthritis patients treated with tocilizumab…

    FibroTest Other

  286. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.

    Shaheen AA et al. · Am J Gastroenterol · 2007 Match 62

    ### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…

    FibroTest Alcohol HBV HCV

  287. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Match 62

    In therapy with standard interferon and ribavirin, five independent risk factors (RF…

    ActiTest FibroTest HCV

  288. Acoustic Radiation Force Impulse Imaging for Diagnosis and Monitoring of Liver Fibrosis in Patients with Hepatitis C: A review of diagnostic accuracy, clinical effectiveness,…

    Match 62

    FibroTest HCV

  289. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.

    Halfon P et al. · Antivir Ther · 2009 Match 61

    ### Background Non-invasive liver fibrosis scores have been proposed as alternatives to…

    FibroTest HCV HIV

  290. Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.

    Mossong J et al. · Bull Soc Sci Med Grand Duche Luxemb · 2011 Match 61

    ### Objective The aim of our study was to assess the diagnostic performance…

    FibroTest HCV

  291. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].

    Supronowicz Ł et al. · Pol Merkur Lekarski · 2013 Match 61

    ### Unlabelled The diagnosis of alcoholic liver disease, steatosis, fibrosis and alcoholic steatohepatitis…

    AshTest FibroTest SteatoTest Alcohol

  292. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

    Myers RP et al. · AIDS · 2003 Match 61

    ### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…

    FibroTest HCV HIV

  293. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.

    Naveau S et al. · Dig Dis Sci · 1994 Match 61

    …and 89% sensitivity for the diagnosis of cirrhosis.(ABSTRACT TRUNCATED AT 250…

    Alcohol

  294. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 61

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  295. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.

    Peta V et al. · Clin Res Hepatol Gastroenterol · 2020 Match 61

    ### Background Haptoglobin bifucosylated tetra-antennary glycan have been identified in patients with…

  296. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 60

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  297. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

    Bedossa P et al. · Hepatology · 1996 Match 60

    Histological activity reflects the global assessment of basic necroinflammatory lesions and is…

    HCV

  298. The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".

    Munteanu M et al. · Gastroenterol Clin Biol · 2009 Match 60

    FibroTest HCV

  299. [The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B].

    Liu WP et al. · Zhonghua Nei Ke Za Zhi · 2008 Match 60

    ### Objective To develop a simple model for the noninvasive diagnosis of liver…

    FibroTest HBV

  300. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 60

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  301. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 60

    ActiTest FibroTest HBV

  302. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022 Match 60

    …While liver biopsy is considered the reference standard for the histologic diagnosis

    FibroTest Metabolic

  303. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 59

    …Most of those deaths could be prevented by an early diagnosis, which…

    FibroTest Alcohol

  304. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Match 59

    Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…

    ActiTest FibroTest HCV

  305. Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.

    · Geriatr Gerontol Int · 2015 Match 59

    FibroTest HCV

  306. Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

    Herman M et al. · Aliment Pharmacol Ther · 2017 Match 59

    FibroTest HCV

  307. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 59

    FibroTest Other

  308. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014 Match 59

    Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…

    FibroTest HBV

  309. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 59

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  310. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

    Halfon P et al. · J Hepatol · 2007 Match 59

    ### Background/Aims We evaluated the test performance profile (TPP) of blood tests…

    FibroTest HCV

  311. Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.

    Munteanu M et al. · Scand J Infect Dis · 2011 Match 58

    ActiTest FibroTest HCV

  312. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 58

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  313. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Match 58

    ### Objective Studies have shown that patients with failing Fontan circulation may develop…

    ActiTest FibroTest Other

  314. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.

    Munteanu M et al. · Clin Biochem · 2008 Match 58

    FibroTest Alcohol HBV HCV +1

  315. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Match 58

    FibroTest HBV

  316. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 58

    FibroTest Metabolic

  317. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

    Rosenthal-Allieri MA et al. · Gastroenterol Clin Biol · 2007 Match 58

    ### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…

    ActiTest FibroTest HCV

  318. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Match 57

    ### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…

    FibroTest Other

  319. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Match 57

    ### Introduction The purpose of this clinical trial was to determine in routine…

    ActiTest FibroTest HCV

  320. [The value of noninvasive serological markers in hepatitis B].

    García-Samaniego J et al. · Gastroenterol Hepatol · 2014 Match 57

    …alternative to biopsies in the diagnosis and monitoring of the progression of…

    FibroTest HBV

  321. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 57

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  322. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication

    Poynard T et al. · Clin Chem · 2007 Match 57

    …of FibroTest (FT) for the diagnosis of advanced fibrosis were estimated in…

    FibroTest HCV

  323. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 57

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  324. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 57

    ActiTest FibroTest HCV

  325. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 56

    Although most hepatitis C virus (HCV) infections are acquired by injection drug…

    FibroTest

  326. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Match 56

    FibroTest HBV

  327. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 56

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  328. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007 Match 56

    Liver stiffness was measured by transient elastography (FibroScan) in 228 consecutive patients…

    FibroTest Alcohol HBV HCV +1

  329. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Match 56

    ### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…

    ActiTest FibroTest HBV

  330. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 56

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  331. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 56

    ### Background Previous research has shown variation in the effects of patient factors…

    FibroTest HCV

  332. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

    Castera L et al. · HIV Med · 2014 Match 56

    ### Objectives Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in…

    FibroTest HCV HIV

  333. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 55

    ActiTest FibroTest HBV

  334. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Match 55

    ### Background Mortality related to complications of cirrhosis is increasing in patients with…

    FibroTest NashTest SteatoTest Metabolic

  335. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 55

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…

    FibroTest SteatoTest Metabolic

  336. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Match 55

    …AUROC curve for the diagnosis of F4 vs F2=0.80 (p…

    FibroTest HCV

  337. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021 Match 55

    ### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…

    ActiTest FibroTest HCV

  338. Analytical variability of the Fibrotest proteins.

    Rosenthal-Allieri MA et al. · Clin Biochem · 2005 Match 55

    ### Objectives The analytical variability of the Fibrotest (FT) parameters raises the issue…

    FibroTest HCV

  339. [SWE elastography in assessment of liver fibrosis].

    Zaleska-Dorobisz U et al. · Postepy Hig Med Dosw (Online) · 2015 Match 55

    Liver fibrosis is a relatively common consequence of chronic liver diseases, especially…

    FibroTest HBV HCV

  340. A reference material for traceability of aspartate aminotransferase (AST) results.

    Férard G et al. · Clin Chem Lab Med · 2005 Match 54

    Standardization of aspartate aminotransferase (AST) determination is highly desirable for inter-laboratory…

    HBV HCV

  341. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 54

    ### Context Recently, it has been shown that an allele in the adiponutrin…

    FibroTest Metabolic

  342. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.

    Sökücü S et al. · Scand J Infect Dis · 2010 Match 54

    The aim of this study was to investigate whether the non-invasive…

    ActiTest FibroTest HBV

  343. Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

    White DL et al. · Dig Dis Sci · 2012 Match 54

    ### Aim We evaluated the association between two medications that alter bioavailable androgen…

    ActiTest FibroTest HCV

  344. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 54

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver…

    FibroTest HCV

  345. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.

    Zeremski M et al. · BMC Gastroenterol · 2014 Match 54

    ### Background Noninvasive markers of liver fibrosis have not been extensively studied in…

    ActiTest FibroTest HBV

  346. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 54

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  347. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.

    Férard G et al. · Clin Chem Lab Med · 2006 Match 53

    Two multi-component scores (Fibrotest and Actitest) have been proposed to evaluate…

    ActiTest FibroTest HBV HCV

  348. Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.

    Bignulin S et al. · Ann Hepatol · 2016 Match 53

    ### Unlabelled Background and rationale. Acoustic radiation force impulse (ARFI) is a non…

    FibroTest HCV

  349. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 53

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  350. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

    Elalfy MS et al. · Ann Hepatol · 2013 Match 53

    ### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…

    ActiTest FibroTest HCV

  351. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 53

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  352. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010 Match 53

    ### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…

    FibroTest HBV HCV

  353. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 53

    BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…

    ActiTest FibroTest Alcohol HBV +3

  354. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 53

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  355. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 52

    ### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…

    FibroTest SteatoTest Other

  356. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 52

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  357. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 52

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  358. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 52

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  359. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 52

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  360. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 52

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  361. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review

    Surial B et al. · Liver Int · 2021 Match 52

    ### Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%-50…

    FibroTest HBV

  362. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 51

    ### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…

    FibroTest HCV

  363. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 51

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  364. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

    Zarski JP et al. · Liver Int · 2010 Match 51

    ### Background The efficacy of a maintenance therapy in non-responder patients with…

    ActiTest FibroTest HCV

  365. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 51

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  366. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 51

    ### Aim This study was undertaken to evaluate the hepatic effects of silybum…

    SteatoTest Metabolic

  367. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 51

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver…

    FibroTest HBV HIV

  368. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.